Natascha Rieder
Penzberg, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.
Journal: Journal for immunotherapy of cancer
Published: February 09, 2026
Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.
Journal: Nature cancer
Published: December 19, 2024
Mapping MAGE-A4 expression in solid cancers for targeted therapies.
Journal: Frontiers in oncology
Published: August 21, 2024
Tumor beta2-microglobulin and HLA-A expression is increased by immunotherapy and can predict response to CIT in association with other biomarkers.
Journal: Frontiers in immunology
Published: August 29, 2023
Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy.
Journal: Cell reports. Medicine
Published: July 06, 2023
A Composite Decision Rule of CD8+ T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 24, 2023
Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 20, 2023
Effects of a communication training for oncologists on early addressing palliative and end-of-life care in advanced cancer care (PALLI-COM): a randomized, controlled trial.
Journal: ESMO open
Published: September 12, 2022
Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition.
Journal: Science translational medicine
Published: June 22, 2020
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 01, 2020
Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-18F-Fluorothymidine Uptake After Therapy in a Colorectal Cancer Model.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 30, 2017
Last Updated: 09/26/2026